KDM4C and acute myeloid leukemia: Dysregulation of JMJD2C has been detected in a variety of tumors, including oesophageal squamous cell carcinoma (ESCC) [45], acute myeloid leukemia (AML) [46], primary mediastinal B cell lymphoma (PMBL), Hodgkin lymphoma (HL) [47], medulloblastoma [48], prostate cancer [49], and breast cancer [50, 39] (Table 1).